The company said, “Management is updating its guidance for the year ending 2025. The company anticipates collaboration revenue to be between $13 million and $18 million, total research and development expenses to be between $130 million and $140 million, and total general and administrative expenses to be between $55 million and $65 million.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Alector reports Q2 EPS (30c), consensus (47c)
- Alector’s Latozinemab Study: A Promising Step in Neurodegenerative Disease Treatment
- Alector upgraded to Outperform from Neutral at Mizuho
- Alector Announces CFO Resignation and Interim Appointment
- Alector CFO Marc Grasso to depart, Neil Berkley appointed Interim CFO